Cimetidine suppression of nocturnal gastric secretion in active duodenal ulcer
- PMID: 2870
- DOI: 10.1056/NEJM197604082941502
Cimetidine suppression of nocturnal gastric secretion in active duodenal ulcer
Abstract
Nocturnal pain and gastric hypersecretion are common in duodenal ulcer. Therefore, we investigated the antisecretory effects of a new H2-receptor antagonist, cimetidine, in 200-, 300- or 400-mg doses, taken orally at bedtime. The 200-mg dose did not cause a statistically significant change in nocturnal (midnight to 7 a.m.) acid output and had only a borderline effect on pH. However, the 300-mg and 400-mg doses significantly (P less than 0.001) lowered acid output and increased (P less than 0.01) intragastric pH. All doses caused substantial decreases in secretory volume output. After a 400-mg dose, half the patients remained anacidic for eight hours. Dose-related increases of drug blood levels were observed and correlated with the degree and duration of inhibition of acid output. Serum gastrin levels were unaffected. Cimetidine appears to be a potent inhibitor of nocturnal gastric secretion.
Similar articles
-
Inhibition of gastric acid secretion by cimetidine in patients with duodenal ulcer.N Engl J Med. 1975 Aug 21;293(8):371-5. doi: 10.1056/NEJM197508212930802. N Engl J Med. 1975. PMID: 239346 Clinical Trial.
-
The effect of cimetidine, a new histamine H2-receptor antagonist, on meal-stimulated acid secretion, serum gastrin, and gastric emptying in patients with duodenal ulcer.Gastroenterology. 1976 Jul;71(1):19-23. Gastroenterology. 1976. PMID: 6359 Clinical Trial.
-
Proceedings: Inhibition of nocturnal acid secretion in duodenal ulcer by oral metiamide.Gut. 1974 Apr;15(4):337. Gut. 1974. PMID: 4151865 Clinical Trial. No abstract available.
-
Postprandial gastric, pancreatic, and biliary response to histamine H2-receptor antagonists active duodenal ulcer.Gastroenterology. 1977 Jan;72(1):9-13. Gastroenterology. 1977. PMID: 11148 Clinical Trial.
-
Clinical effects of trithiozine, a newer gastric anti-secretory agent.J Int Med Res. 1979;7(5):452-8. doi: 10.1177/030006057900700521. J Int Med Res. 1979. PMID: 387498 Review.
Cited by
-
Rebound nocturnal hypersecretion after four weeks treatment with an H2 receptor antagonist.Gut. 1989 Apr;30(4):449-54. doi: 10.1136/gut.30.4.449. Gut. 1989. PMID: 2565860 Free PMC article.
-
The preventive effect of cimetidine on producing stress ulcer in rats.Jpn J Surg. 1978 Sep;8(3):242-7. doi: 10.1007/BF02469450. Jpn J Surg. 1978. PMID: 723018
-
Cimetidine for ever (and ever and ever...)?Br Med J. 1978 Jun 3;1(6125):1435-6. doi: 10.1136/bmj.1.6125.1435. Br Med J. 1978. PMID: 647322 Free PMC article. No abstract available.
-
Clinical pharmacokinetics of famotidine.Clin Pharmacokinet. 1991 Sep;21(3):178-94. doi: 10.2165/00003088-199121030-00003. Clin Pharmacokinet. 1991. PMID: 1764869 Review.
-
A controlled study comparing cimetidine treatment to an intensive antacid regimen in the therapy of uncomplicated duodenal ulcer.Dig Dis Sci. 1979 Oct;24(10):758-62. doi: 10.1007/BF01317208. Dig Dis Sci. 1979. PMID: 487912 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources